Madrigal Pharmaceuticals, Inc. (MDGL) income statement
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$398.08−23.91 (-5.67%)
Close on Nov 18, 2026Market cap $9.20BP/E –Yield –
Madrigal Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -25.1%
- Net margin
- -25.3%
- Return on equity, FY2025
- -42.5%
Financial strength
- Current ratio
- 3.20
- Debt to equity
- 0.65
- Debt to assets
- 27.4%
- Cash to current liabilities
- 78.2%
Valuation
- P/E ratio
- –
- Price to sales
- 7.16
- Price to book
- 17.56
- Dividend yield
- –
See a number that looks wrong?